$OMER
OMEROS CORP Stock $omer

$omer Overview Financials Valuation SEC Filings Company Website

2017 Q2 Form 10-Q Financial Statement

#000128581917000008 Filed on May 10, 2017

Income Statement

Concept	2017 Q2	2017 Q1	2016 Q1
Revenue	$17.15M	$12.26M	$7.419M
YoY Change	71.44%	65.21%	1812.11%
Cost Of Revenue	$157.0K	$271.0K	$327.0K
YoY Change	-51.99%	-17.13%	2872.73%
Gross Profit	$16.99M	$11.99M	$7.092M
YoY Change	75.61%	69.01%	1781.17%
Gross Profit Margin	99.08%	97.79%	95.59%
Selling, General & Admin	$15.80M	$12.47M	$11.11M
YoY Change	52.22%	12.24%	23.58%
% of Gross Profit	92.97%	104.04%	156.66%
Research & Development	$13.14M	$12.24M	$15.43M
YoY Change	28.4%	-20.69%	65.64%
% of Gross Profit	77.3%	102.12%	217.63%
Depreciation & Amortization	$110.0K	$120.0K	$50.00K
YoY Change	57.14%	140.0%	-16.67%
% of Gross Profit	0.65%	1.0%	0.71%
Operating Expenses	$29.09M	$24.98M	$26.87M
YoY Change	38.97%	-7.03%	46.69%
Operating Profit	-$11.94M	-$12.73M	-$19.45M
YoY Change	9.24%	-34.58%	8.49%
Interest Expense	$2.723M	$2.663M	$1.375M
YoY Change	46.63%	93.67%	43.68%
% of Operating Profit
Other Income/Expense, Net	$303.0K	$299.0K	$288.0K
YoY Change	74.14%	3.82%	32.11%
Pretax Income	-$14.36M	-$15.09M	-$20.54M
YoY Change	13.88%	-26.53%	10.02%
Income Tax
% Of Pretax Income
Net Earnings	-$14.36M	-$15.09M	-$20.54M
YoY Change	13.85%	-26.53%	10.02%
Net Earnings / Revenue	-83.72%	-123.11%	-276.84%
Basic Earnings Per Share
Diluted Earnings Per Share	-$326.1K	-$344.3K	-$536.0K
COMMON SHARES
Basic Shares Outstanding	43.94M shares	43.82M shares	38.26M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q2	2017 Q1	2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$29.70M	$33.70M	$13.20M
YoY Change	40.09%	155.3%	-81.17%
Cash & Equivalents	$3.386M	$1.282M	$978.0K
Short-Term Investments	$26.30M	$32.40M	$12.30M
Other Short-Term Assets	$3.400M	$3.300M	$2.500M
YoY Change	47.83%	32.0%	2055.17%
Inventory	$905.0K	$960.0K	$1.972M
Prepaid Expenses	$3.446M	$3.260M	$2.460M
Receivables	$19.10M	$13.50M	$6.600M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$53.09M	$51.35M	$24.32M
YoY Change	55.68%	111.14%	-66.71%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.426M	$1.215M	$898.0K
YoY Change	13.99%	35.3%	23.52%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$5.800M	$5.800M	$73.00K
YoY Change	7845.21%	7845.21%	-83.37%
Total Long-Term Assets	$7.261M	$7.050M	$11.65M
YoY Change	-39.51%	-39.48%	531.44%
TOTAL ASSETS
Total Short-Term Assets	$53.09M	$51.35M	$24.32M
Total Long-Term Assets	$7.261M	$7.050M	$11.65M
Total Assets	$60.35M	$58.40M	$35.97M
YoY Change	30.9%	62.36%	-51.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.572M	$2.409M	$5.332M
YoY Change	-52.55%	-54.82%	15.64%
Accrued Expenses	$21.64M	$14.34M	$12.12M
YoY Change	107.07%	18.28%	88.26%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$250.0K	$228.0K	$69.00K
YoY Change	29.53%	230.43%	-99.23%
Total Short-Term Liabilities	$24.75M	$16.97M	$17.52M
YoY Change	54.08%	-3.13%	-12.69%
LONG-TERM LIABILITIES
Long-Term Debt	$81.51M	$80.50M	$49.97M
YoY Change	16.72%	61.09%	109.04%
Other Long-Term Liabilities	$8.900M	$9.000M	$9.200M
YoY Change	-3.26%	-2.17%	1.1%
Total Long-Term Liabilities	$81.51M	$80.50M	$49.97M
YoY Change	16.72%	61.09%	109.04%
TOTAL LIABILITIES
Total Short-Term Liabilities	$24.75M	$16.97M	$17.52M
Total Long-Term Liabilities	$81.51M	$80.50M	$49.97M
Total Liabilities	$106.3M	$97.48M	$67.49M
YoY Change	23.71%	44.42%	53.49%
SHAREHOLDERS EQUITY
Retained Earnings	-$499.3M	-$485.0M	-$423.7M
YoY Change	14.45%	14.47%	22.2%
Common Stock	$444.0K	$439.0K	$391.0K
YoY Change	12.98%	12.28%	3.44%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$54.85M	-$48.11M	-$40.74M
YoY Change
Total Liabilities & Shareholders Equity	$60.35M	$58.40M	$35.97M
YoY Change	30.9%	62.36%	-51.98%

Cashflow Statement

Concept	2017 Q2	2017 Q1	2016 Q1
OPERATING ACTIVITIES
Net Income	-$14.36M	-$15.09M	-$20.54M
YoY Change	13.85%	-26.53%	10.02%
Depreciation, Depletion And Amortization	$110.0K	$120.0K	$50.00K
YoY Change	57.14%	140.0%	-16.67%
Cash From Operating Activities	-$8.160M	-$12.70M	-$16.63M
YoY Change	-36.2%	-23.61%	-4.85%
INVESTING ACTIVITIES
Capital Expenditures	-$250.0K	$72.00K	$0.00
YoY Change	733.33%
Acquisitions
YoY Change
Other Investing Activities	$6.090M	$10.74M	$14.63M
YoY Change	-239.04%	-26.59%	-123.56%
Cash From Investing Activities	$5.850M	$10.66M	$14.63M
YoY Change	-232.65%	-27.12%	-123.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$1.147M	$7.500K
YoY Change		15193.33%	-99.99%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.410M	$1.096M	$1.609M
YoY Change	-78.82%	-31.88%	-98.01%
NET CHANGE
Cash From Operating Activities	-8.160M	-$12.70M	-$16.63M
Cash From Investing Activities	5.850M	$10.66M	$14.63M
Cash From Financing Activities	4.410M	$1.096M	$1.609M
Net Change In Cash	2.100M	-$942.0K	-$387.0K
YoY Change	-41.99%	143.41%	-135.6%
FREE CASH FLOW
Cash From Operating Activities	-$8.160M	-$12.70M	-$16.63M
Capital Expenditures	-$250.0K	$72.00K	$0.00
Free Cash Flow	-$7.910M	-$12.77M	-$16.63M
YoY Change	-38.01%	-23.18%	-4.85%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q1	dei	Amendment Flag AmendmentFlag	false
CY2017Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2017Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017Q1	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
CY2017Q1	dei	Document Type DocumentType	10-Q
CY2017Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001285819
CY2017Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	43939513	shares
CY2017Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2017Q1	dei	Entity Registrant Name EntityRegistrantName	OMEROS CORP
CY2017Q1	dei	Trading Symbol TradingSymbol	OMER
CY2016Q4	omer	Accrued Clinical Trial Costs AccruedClinicalTrialCosts	1167000	USD
CY2017Q1	omer	Accrued Clinical Trial Costs AccruedClinicalTrialCosts	999000	USD
CY2016Q4	omer	Accrued Contract Research Costs AccruedContractResearchCosts	3030000	USD
CY2017Q1	omer	Accrued Contract Research Costs AccruedContractResearchCosts	3751000	USD
CY2017Q1	omer	Effective Income Tax Rate Reconciliation Sharebased Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount	4500000	USD
CY2017Q1	omer	Long Term Purchase Commitment Termination Fee LongTermPurchaseCommitmentTerminationFee	2700000	USD
CY2016Q1	omer	Noncash Transaction Conversion Of Accrued Interest Into Notes Payable NoncashTransactionConversionOfAccruedInterestIntoNotesPayable	0	USD
CY2017Q1	omer	Noncash Transaction Conversion Of Accrued Interest Into Notes Payable NoncashTransactionConversionOfAccruedInterestIntoNotesPayable	805000	USD
CY2016Q1	omer	Proceedsfrom Stock Optionsand Warrants Exercised ProceedsfromStockOptionsandWarrantsExercised	1609000	USD
CY2016Q1	omer	Proceedsfrom Stock Optionsand Warrants Exercised ProceedsfromStockOptionsandWarrantsExercised	1600000	USD
CY2017Q1	omer	Proceedsfrom Stock Optionsand Warrants Exercised ProceedsfromStockOptionsandWarrantsExercised	1147000	USD
CY2016Q1	omer	Stock Issued During Period Shares Stock Optionsand Warrants Exercised StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised	329013	shares
CY2017Q1	omer	Stock Issued During Period Shares Stock Optionsand Warrants Exercised StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised	117898	shares
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2519000	USD
CY2017Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2409000	USD
CY2016Q4	us-gaap	Accrued Exchange Fee Rebate Current AccruedExchangeFeeRebateCurrent	1335000	USD
CY2017Q1	us-gaap	Accrued Exchange Fee Rebate Current AccruedExchangeFeeRebateCurrent	2098000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13354000	USD
CY2017Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14336000	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2223000	USD
CY2017Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3726000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	432002000	USD
CY2017Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	436424000	USD
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9302348	shares
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11024664	shares
CY2016Q4	us-gaap	Assets Assets	67278000	USD
CY2017Q1	us-gaap	Assets Assets	58404000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	60262000	USD
CY2017Q1	us-gaap	Assets Current AssetsCurrent	51354000	USD
CY2016Q4	us-gaap	Available For Sale Securities Equity Securities Current AvailableForSaleSecuritiesEquitySecuritiesCurrent	43107000	USD
CY2017Q1	us-gaap	Available For Sale Securities Equity Securities Current AvailableForSaleSecuritiesEquitySecuritiesCurrent	32371000	USD
CY2016Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	522000	USD
CY2017Q1	us-gaap	Capital Lease Obligations CapitalLeaseObligations	549000	USD
CY2016Q1	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	USD
CY2017Q1	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	70000	USD
CY2016Q4	us-gaap	Cash Cash	2200000	USD
CY2017Q1	us-gaap	Cash Cash	1300000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1365000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	978000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2224000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1282000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-387000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-942000	USD
CY2017Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	33700000	USD
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	43819133	shares
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	43937031	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	438000	USD
CY2017Q1	us-gaap	Common Stock Value CommonStockValue	439000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20539000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15089000	USD
CY2016Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	327000	USD
CY2017Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	271000	USD
CY2016Q4	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	85063000	USD
CY2015Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	749250	shares
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	43819133	shares
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	43937031	shares
CY2017Q1	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	85936000	USD
CY2016Q4	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	3958000	USD
CY2017Q1	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	3859000	USD
CY2016Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	1395000	USD
CY2017Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	1346000	USD
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	9142000	USD
CY2017Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	9041000	USD
CY2016Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	53000	USD
CY2017Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	115000	USD
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.54
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4551000	USD
CY2017Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2704000	USD
CY2017Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	24900000	USD
CY2016Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11110000	USD
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12471000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1272000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	771000	USD
CY2016Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1500000	USD
CY2017Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-168000	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	420000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1494000	USD
CY2016Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	129000	USD
CY2017Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	1444000	USD
CY2016Q1	us-gaap	Interest Expense InterestExpense	1375000	USD
CY2017Q1	us-gaap	Interest Expense InterestExpense	2663000	USD
CY2016Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	173000	USD
CY2016Q1	us-gaap	Interest Paid InterestPaid	776000	USD
CY2017Q1	us-gaap	Interest Paid InterestPaid	1667000	USD
CY2017Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	163000	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	1128000	USD
CY2017Q1	us-gaap	Inventory Net InventoryNet	960000	USD
CY2016Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	101000	USD
CY2017Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	101000	USD
CY2016Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	854000	USD
CY2017Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	696000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	67278000	USD
CY2017Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	58404000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16071000	USD
CY2017Q1	us-gaap	Liabilities Current LiabilitiesCurrent	16973000	USD
CY2016Q4	us-gaap	Loans Payable LoansPayable	4025000	USD
CY2017Q1	us-gaap	Loans Payable LoansPayable	4066000	USD
CY2017Q1	us-gaap	Loans Payable LoansPayable	4100000	USD
CY2016Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	198000	USD
CY2017Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	228000	USD
CY2016Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	79512000	USD
CY2017Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	80503000	USD
CY2016	us-gaap	Loss Contingency Patents Allegedly Infringed Number LossContingencyPatentsAllegedlyInfringedNumber	3	patent
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1609000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1096000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	14632000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	10664000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16628000	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	51500000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12700000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12702000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-20539000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	66700000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-15089000	USD
CY2016Q4	us-gaap	Notes Payable NotesPayable	80516000	USD
CY2017Q1	us-gaap	Notes Payable NotesPayable	81321000	USD
CY2017Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	26871000	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	24982000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-19452000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-12725000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1048000	USD
CY2017Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1058000	USD
CY2016Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	288000	USD
CY2017Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	299000	USD
CY2016Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	213000	USD
CY2017Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	995000	USD
CY2016Q1	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	18000	USD
CY2017Q1	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	1042000	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	72000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2017Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1766000	USD
CY2017Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	3260000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	7500	USD
CY2016Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	14650000	USD
CY2017Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	11778000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1181000	USD
CY2017Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1215000	USD
CY2017Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	12037000	USD
CY2017Q1	us-gaap	Receivables Net Current ReceivablesNetCurrent	13481000	USD
CY2016Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2017Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	51000	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15434000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12240000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	5835000	USD
CY2017Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	5835000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-469887000	USD
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-484976000	USD
CY2016Q1	us-gaap	Revenue From Grants RevenueFromGrants	173000	USD
CY2017Q1	us-gaap	Revenue From Grants RevenueFromGrants	0	USD
CY2016Q1	us-gaap	Revenues Revenues	7419000	USD
CY2017Q1	us-gaap	Revenues Revenues	12257000	USD
CY2016Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	7246000	USD
CY2017Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	12257000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4422000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3276000	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1061046	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	6817595	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	8.97
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	242714	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	10.44
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1475300	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	58215000	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9809374	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10924062	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.66
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.88
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	56632000	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	10510973	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	9.82
CY2017Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	9.74
CY2017Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	11.55
CY2015Q1	us-gaap	Share Price SharePrice	20.03
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	42519000	USD
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y1M6D
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M10D
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y2M15D
CY2015Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3400000	shares
CY2017Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	117898	shares
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	-37447000	USD
CY2017Q1	us-gaap	Stockholders Equity StockholdersEquity	-48113000	USD
CY2016	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	USD
CY2017Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	USD
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38317084	shares
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	43828572	shares
CY2017Q1	us-gaap	Revenue Recognition Sales Of Goods RevenueRecognitionSalesOfGoods	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Product Sales, Net</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We record revenue from product sales when the product is delivered to our wholesalers. Product sales to a wholesaler are not recorded if we determine that the wholesaler’s on-hand OMIDRIA inventory, based on sell-through and inventory information we regularly receive from our wholesalers, exceeds approximately eight weeks of projected demand.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product sales are recorded net of wholesaler distribution fees and estimated chargebacks, product returns and rebates. Accruals or allowances are established for these deductions in the same period when revenue is recognized, and actual amounts incurred are offset against the applicable accruals or allowances. We reflect each of these accruals or allowances as either a reduction in the related account receivable or as an accrued liability, depending on how the amount is expected to be settled.</font></div></div>
CY2017Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant items subject to such estimates include revenue recognition, fair market value of investments, stock-based compensation expense and accruals for clinical trials and contingencies. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances; however, actual results could differ from these estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001285819-17-000008-index-headers.html	Edgar Link	pending
0001285819-17-000008-index.html	Edgar Link	pending
0001285819-17-000008.txt	Edgar Link	pending
0001285819-17-000008-xbrl.zip	Edgar Link	pending
ex101_20170331.htm	Edgar Link	pending
ex121_20170331.htm	Edgar Link	pending
ex311_20170331.htm	Edgar Link	pending
ex312_20170331.htm	Edgar Link	pending
ex321_20170331.htm	Edgar Link	pending
ex322_20170331.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
omer-20170331.xml	Edgar Link	completed
omer-20170331.xsd	Edgar Link	pending
omer-20170331x10q.htm	Edgar Link	pending
omer-20170331_cal.xml	Edgar Link	unprocessable
omer-20170331_def.xml	Edgar Link	unprocessable
omer-20170331_lab.xml	Edgar Link	unprocessable
omer-20170331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OMER
OMEROS CORP Stock $omer

2017 Q2 Form 10-Q Financial Statement

#000128581917000008 Filed on May 10, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OMER OMEROS CORP Stock $omer

2017 Q2 Form 10-Q Financial Statement

#000128581917000008 Filed on May 10, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OMER
OMEROS CORP Stock $omer